From the Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology.
Division of Surgical-Oncology, Department of Surgery.
Clin Nucl Med. 2023 Jul 1;48(7):e353-e355. doi: 10.1097/RLU.0000000000004689. Epub 2023 May 6.
A 43-year-old man with a growing mass in the right groin, concerned for liposarcoma, underwent MRI and 68 Ga-fibroblast activation protein inhibitor (FAPI)-46 PET/CT before surgery. Fibroblast activation protein inhibitor PET/CT demonstrated increased uptake (SUV max , 3.2) predominantly in the solid portion, where MRI showed gadolinium enhancement. The patient subsequently underwent surgery and was diagnosed with hibernoma. The immunohistochemistry of the tumor revealed the fibroblast activation protein expression in the fibrovascular network and myofibroblastic cells of the tumor. This case suggests that the FAPI uptake can be affected by the vascular cells, and thus, a careful interpretation of the FAPI PET signal may be needed.
一位 43 岁男性，右侧腹股沟区肿块逐渐增大，担心为脂肪肉瘤，在手术前进行了 MRI 和 68Ga-成纤维细胞激活蛋白抑制剂（FAPI）-46 PET/CT 检查。FAPI-PET/CT 显示摄取增加（SUVmax，3.2），主要位于实性部分，MRI 显示钆增强。患者随后接受了手术，诊断为冬眠瘤。肿瘤的免疫组化显示纤维血管网络和肿瘤的肌纤维母细胞中存在成纤维细胞激活蛋白表达。该病例提示 FAPI 摄取可能受血管细胞的影响，因此需要仔细解读 FAPI PET 信号。
